Alemtuzumab CARE-MS I 5-year follow-up
Neurol 89:1107-1116, Havrdova, E.,et al, 2017
Alemtuzumab CARE-MS II 5-year follow-up
Neurol 89:1117-1126, Coles, A.J.,et al, 2017
Evolution of DWI lesions in Cerebral Amyloid Angiopathy
Neurol 89:2136-2142, Van Veluw, S.J.,et al, 2017
Imaging Characteristics of Venous Parenchymal Abnormalities
Stroke 48:3258-3265, Arnoux, A.,et al, 2017
Clemastine Fumarate as a Remyelinating Therapy for Multiple Sclerosis (ReBUILD): A Randomised, Controlled, Double-Blind, Crossover Trial
Lancet 390:2481-2489, Green, A.J.,et al, 2017
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 376:221-234,280, Hauser, S.L.,et al, 2017
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
NEJM 376:209-220,280, Montalban, X.,et al, 2017
Have Clinicians Adopted the Use of Brain MRI for Patients with TIA and Minor Stroke?
Neurol 88:237-244, Chaturvedi, S.,et al, 2017
Characteristics in Limbic Encephalitis with Anti-Adenylate Kinase 5 Autoantibodies
Neurol 88:514-524,508, Do, L. & Chanson, E., 2017
Natalizumab-Associated PML
Neurol 88:1197-1205, Schwab, N.,et al, 2017
Long-Term Outcomes after Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis
JAMA Neurol 74:459-469,392, Muraro, P.A.,et al, 2017
Primary Angiitis of the Central Nervous System
Stroke 48:1248-1255, Boulouis, G.,et al, 2017
Distribution of Lacunes in Cerebral Amyloid Angiopathy and Hypertensive Small Vessel Disease
Neurol 88:2162-2168, Pasi, M.,et al, 2017
Acute Cholecystitis During Treatment with Alemtuzumab in 3 Patients with RRMS
Neurol 87:2380-2381, Pfeuffer, S.,et al, 2016
Central Canal Enhancement and the Trident Sign in Spinal Cord Sarcoidosis
Neurol 87:743-744, Zalewski, N.L.,et al, 2016
Herpes Simplex Encephalitis in an Immunocompromised Adult with Novel MRI and Pathology Findings
Clin Neuroradiol DOI: 10.1007/s00062-016-0536-x, Modak, J.,et al, 2016
The Contemporary Spectrum of Multiple Sclerosis Misdiagnosis
Neurol 87:1393-1399, Solomon, A.J.,et al, 2016
Superior MRI Outcomes with Alemtuzumab Compared with Subcutaneous Interferon �-1a in MS
Neurol 87:1464-1472, Arnold, D.L.,et al, 2016
Emerging Risk Factors for Recurrent Vascular Events in Patients with Embolic Stroke of Unertermined Source
Stroke 47:2714-2721, Ueno, Y.,et al, 2016
Punctate Pattern, A promising imaging marker for the diagnosis of natalizumab-associated PML
Neurol 86:1516-1523, Hodel, J.,et al, 2016
Zika Virus Associated with Meningoencephalitis
NEJM 374:1595-1596, Carteau, G.,et al, 2016
Longitudinally Extensive Spinal Cord Lesions Disclosing Occult Systemic Sarcoidosis
JAMA Neurol 73:600-601, Sechi, E.,et al, 2016
Clinicopathologic Conference, Neurosarcoidosis
NEJM 374:1966-1975, Case 15-2016, 2016
Neurologic Signs and Symptoms Frequently Manifest in Acute HIV Infection
Neurol 87:148-154, Hellmuth, J.,et al, 2016
Clinicopathologic Conference, Somnolence due to the Cerebral Fat Embolism Syndrome
NEJM 375:370-378, Case 23-2016, 2016
Pseudoradial Nerve Palsy Caused by Acute Ischemic Stroke
J Invest Med Case Report doi:10.1177/2324709616658310, Tahir, H.,et al, 2016
Marburgs Variant of Multiple Sclerosis with Extensive Brain Lesions
Int J Neurol Neurother doi:10.23937/2378-3001/2/1/1027, Ludwig, A.,et al, 2015
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 373:1418-1428, Kappos, L.,et al, 2015
A Young Woman with Blurred Vision and Distal Paresthesias
JAMA Neurol 72:1519-1523, Kung, N.H.,et al, 2015
SLIPPERS: Supratentorial Lymphocytic Inflammation with Parenchymal Perivascular Enhancement Responsive to Steroids
Neurol 84: Suppl P5.118, Armand, C.,et al, 2015
Relapse in Multiple Sclerosis
BMJ 350:h1765, Galea, I.,et al, 2015
Oral Versus Intravenous High-Dose Methylprednisolone for Treatment of Relapses in Patients with Multiple Sclerosis (COPOUSEP):A Randomised, Controlled, Double-Blind,Non-Inferiority Trial
Lancet 386:974-981, LePage,E.,et al, 2015
A 73-year-old Man with Diplopia and Ataxia
Neurol 85:e96-e100, Gupta, H.V.,et al, 2015
Safety and Efficacy of Ofatumumab in Relapsing-Remitting Multiple Sclerosis
Neurol 82:573-581, Sorensen, P.S.,et al, 2014
Evaluation of Cryptogenic Stroke with Advanced Diagnostic Techniques
Stroke 45:1186-1194, Bang, O.Y.,et al, 2014
DWI Reversal is Associated with Small Infarct Volume in Patient with TIA and Minor Stroke
AJNR 35:660-666, Asdaghi, N.,et al, 2014
Dynamic MR Imaging Patterns of Cerebral Fat Embolism: A Systematic Review with Illustrative Cases
AJNR 35:1052-1057, Kuo, K.H.,et al, 2014
Remote or Extraischemic Intracerebral Hemorrhage - An Uncommon Complication of Stroke Thrombolysis
Stroke 45:1657-1663, Mazya, M.V.,et al, 2014
IgG4-Related Hypertrophic Pachymeningitis
JAMA Neurol 71:785-793, Lu, L.X.,et al, 2014
Amyloid-Beta Related Angiitis of the Central Nervous System: Case Report and Topic Review
Front Neurol 5:1-4, Nouh, A.,et al, 2014
Small Strokes Causing Severe Vertigo
Neurol 83:169-173, Tehrani, A.S.S.,et al, 2014
Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab
JAMA Neurol 71:954-960, Clerico, M.,et al, 2014
CD49d Antisense Drug ATL1102 Reduces Disease Activity in Patients with Relapsing-Remitting MS
Neurol 83:1780-1788, Limmroth, V.,et al, 2014
Enhancing Brain Lesions after Endovascular Treatment of Aneurysms
AJNR 35:1954-1958, Cruz, J.P.,et al, 2014
Progressive Cerebellar Ataxia and New-Onset Diabetes
Lancet 383:186, Kong, M.,et al, 2014
Paraneoplastic Neurological Syndromes
Clin Exp Immunol 175:336-348, Leypoldt, F. & Wandinger, K.-P., 2014
Neurocandidiasis: A Case Report and Consideration of the Causes of Restricted Diffusion
Radiology Cases 7:1-5, Lin, D.J.,et al, 2013
Three Times Weekly Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis
Ann Neurol 73:705-713, Khan, O.,et al, 2013
Extending the KCNQ2 encephalopathy Spectrum
Neurol 81:1697-1703, Weckhuysen, S.,et al, 2013
Daclizumab High-Yield Process in Relapsing-Remitting Multiple Sclerosis (SELECT): A Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 381:190-194, Gold, R.,et al, 2013